A Predictive Phosphorylation Signature of Lung Cancer by Wu, Chang-Jiun et al.
Boston University
OpenBU http://open.bu.edu
Biomedical Engineering ENG: Biomedical Engineering: Scholarly Papers
2009-11-25
A Predictive Phosphorylation
Signature of Lung Cancer
Wu, Chang-Jiun, Tianxi Cai, Klarisa Rikova, David Merberg, Simon Kasif, Martin
Steffen. "A Predictive Phosphorylation Signature of Lung Cancer" PLoS ONE 4(11):
e7994. (2009)
https://hdl.handle.net/2144/3056
Boston University
A Predictive Phosphorylation Signature of Lung Cancer
Chang-Jiun Wu1, Tianxi Cai2, Klarisa Rikova3, David Merberg4, Simon Kasif1,5,6., Martin Steffen1,7.*
1Department of Biomedical Engineering, Boston University, Boston, Massachusetts, United States of America, 2Department of Biostatistics, Harvard School of Public
Health, Boston, Massachusetts, United States of America, 3Cell Signaling Technology, Danvers, Massachusetts, United States of America, 4 Vertex Pharmaceuticals,
Cambridge, Massachusetts, United States of America, 5Children’s Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, Boston,
Massachusetts, United States of America, 6Center for Advanced Genomic Technology, Boston University, Boston, Massachusetts, United States of America, 7Department
of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America
Abstract
Background: Aberrant activation of signaling pathways drives many of the fundamental biological processes that
accompany tumor initiation and progression. Inappropriate phosphorylation of intermediates in these signaling pathways
are a frequently observed molecular lesion that accompanies the undesirable activation or repression of pro- and anti-
oncogenic pathways. Therefore, methods which directly query signaling pathway activation via phosphorylation assays in
individual cancer biopsies are expected to provide important insights into the molecular ‘‘logic’’ that distinguishes cancer
and normal tissue on one hand, and enables personalized intervention strategies on the other.
Results: We first document the largest available set of tyrosine phosphorylation sites that are, individually, differentially
phosphorylated in lung cancer, thus providing an immediate set of drug targets. Next, we develop a novel computational
methodology to identify pathways whose phosphorylation activity is strongly correlated with the lung cancer phenotype.
Finally, we demonstrate the feasibility of classifying lung cancers based on multi-variate phosphorylation signatures.
Conclusions: Highly predictive and biologically transparent phosphorylation signatures of lung cancer provide evidence for
the existence of a robust set of phosphorylation mechanisms (captured by the signatures) present in the majority of lung
cancers, and that reliably distinguish each lung cancer from normal. This approach should improve our understanding of
cancer and help guide its treatment, since the phosphorylation signatures highlight proteins and pathways whose
phosphorylation should be inhibited in order to prevent unregulated proliferation.
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Introduction
At the molecular level, cancers are heterogeneous diseases,
arising from genetic factors, environmental carcinogens and
random, somatic mutation [1]. Phosphorylation of proteins is a
key regulator of protein activity [2], and in particular, modification
of tyrosine residues modulate critical signaling and control
processes [3]. In cancers, aberrant phosphorylation status of key
residues (its presence or absence) has been observed and
documented in many studies, which include the original oncogene,
src [4], and many others [5].
Signatures based on protein levels are starting to be developed
[6]. Protein levels are expected to be strongly correlated with
phenotype and protein-based diagnostics can be easily imple-
mented in most major medical centers. Monitoring the functional
status of proteins may therefore be highly germane to clinical
applications, and offer an additional layer of specificity for
enhancing our scientific understanding of causal progression of
disease. Methods for high-throughput detection of phosphorylated
residues using mass spectrometry are being rapidly developed
[7,8,9,10] and applied to the study of signaling pathways [11]
along with complementary analysis and modeling approaches
[12,13].
In this paper, we examined global tyrosine phosphorylation data
from lung cancers and normal lung tissue [14], seeking to identify
differentially phosphorylated protein sites and differentially
activated pathways, and to assess their suitability as classifiers.
We report a large set of sites that are differentially phosphorylated
in tumors, many of which can be used as direct targets for new
drugs. We present evidence that certain pathways are differentially
activated, based on their global phosphorylation status using a
novel computational approach to perform a protein variant of
gene set enrichment analysis.
We then demonstrate that a relatively small number of
phosphorylated peptides observed in that data [14] can discrim-
inate between normal tissue and tumor with exquisite sensitivity
and specificity. We validate our phosphorylation signature using
rigorous cross validation and testing on a previously unpublished
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independent set. Finally, we compare the binding affinities of
multiple kinase inhibitors with the phosphorylation activity of their
targets in our study. The integration with pharmaceutical data
leads to interesting hypotheses about the relative efficacy of such
drugs and suggests unexplored but potentially potent lung cancer
agents, highlighting potential clinical applications.
There is a fundamental distinction between predictive signa-
tures, such as the ones developed here, and the observation that a
protein is differentially expressed (or phosphorylated) with
statistical significance. In principle, a protein may be differentially
phosphorylated but be of little predictive utility for the broad
classification of a disease or for devising a personalized treatment
strategy. Differential phosphorylation of a protein is a population
aggregate summary. It means that, on average, the phosphoryla-
tion level of a protein is higher or lower in a cancer than normal
tissue. However, for any given patient the probability of error in
classifying the biopsy as a cancer could be as high as 0.49 (if the
distributions of the measurements for cancer and normal tissues
overlap). No account of disease heterogeneity is considered, and
elevated levels could result solely from a subset of the disease cases.
Conversely, a signature with high predictive value suggests that the
phospho-sites included in the signature are part of a core set of
pathways that are universally operative in the disease. They are
therefore potentially reflective of a universal pathogenetic
mechanism for that disease, and can lead to the discovery of a
‘‘phosphorylation logic’’ that captures the tissue specific, or even a
general, neoplastic phenotype. Heterogeneous cancer sub-types
will necessarily require more complex signatures, requiring a large
set of predictive mechanisms that can provide high-coverage of the
differential activity of key pathways in the specific cancer. Finally,
if the predictive signatures consist of a small set of proteins that
implicate specific pathways (as implied by our work), this set of
pathways becomes a prime target for a broad combinatorial multi-
target drug strategy.
Results
Multiple Tyrosine Sites Are Differentially Phosphorylated
in Lung Cancer Tissue
We first analyzed individual protein sites to determine those that
are differentially phosphorylated between the 48 normal and 94
non-small cell lung cancer (NSCLC) tumor samples. Our results
reveal 129 unique amino acid sites that were significantly
differentially phosphorylated between normal and tumor samples
(false discovery rate, FDR q value ,0.05). Of these, 77 of the sites
were more phosphorylated in cancerous tissue and 52 sites were
more phosphorylated in normal tissue. Table 1 lists the highest-
ranking 20 protein sites with the smallest ranksum p values, with all
sites listed in Table S1.
In addition to the top genes listed in the table many other
prominent markers of cancer were detected in our analysis. In
particular, EGFR is a receptor tyrosine kinase implicated in lung
cancer and is involved in multiple biological processes, including
apoptosis, cell adhesion, and growth [15,16,17]. Mutations of
EGFR are seen in a set of NSCLC patients with good response to
EGFR inhibitor [18,19]. The phosphorylation statuses of two
Table 1. The 20 protein sites most differentially phosphorylated between normal and NSCLC samples.
Index ID T/N SCR* P-value** FDR*** Description
1 ADH1B_34 0.08 5.13E-12 1.35E-09 Alcohol dehydrogenase IB (class I), beta polypeptide
2 CAV1_14 0.15 2.13E-11 2.27E-09 caveolin 1, caveolae protein, 22kDa
3 TNS1_1149 0.16 2.58E-11 2.27E-09 tensin 1
4 C11ORF52_103 0.13 4.32E-11 2.85E-09 chromosome 11 open reading frame 52
5 GAB1_659 0.17 3.26E-10 1.72E-08 GRB2-associated binding protein 1
6 TNS1_1326 0.19 8.84E-10 3.89E-08 tensin 1
7 ANXA2_29 0.2 4.40E-09 1.66E-07 Annexin A2
8 TNS1_1404 0.13 1.12E-08 3.62E-07 tensin 1
9 STAT1_701 0.05 1.23E-08 3.62E-07 signal transducer and activator of transcription 1,
91kDa
10 LYN;HCK_396;410 3.87 3.46E-08 9.14E-07 v-yes-1 Yamaguchi sarcoma viral related oncogene
homolog //// hemopoietic cell kinase
11 CDC2_15 9.36 7.75E-08 1.86E-06 cell division cycle 2, G1 to S and G2 to M
12 CDC2_15,19 13.45 1.25E-07 2.75E-06 cell division cycle 2, G1 to S and G2 to M
13 C19ORF59_38 0.08 1.40E-07 2.84E-06 chromosome 19 open reading frame 59
14 SEPT2_17 0.08 1.71E-07 3.23E-06 septin 2
15 TNS1_1323 0.14 1.86E-07 3.27E-06 tensin 1
16 C11ORF52_78 0.09 2.06E-07 3.41E-06 chromosome 11 open reading frame 52
17 TJP2_1118 0.25 3.55E-07 5.51E-06 tight junction protein 2 (zona occludens 2)
18 PTTG1IP_174 4.03 8.59E-07 1.26E-05 pituitary tumor-transforming 1 interacting protein
19 MAPK13_182 2.72 1.03E-06 1.39E-05 mitogen-activated protein kinase 13
20 PIK3R2_464 4.87 1.05E-06 1.39E-05 phosphoinositide-3-kinase, regulatory subunit 2 (p85
beta)
*T/N SCR: Tumor/normal phosphorylation spectral count ratio;
**P-value: significance of difference between two sample groups with rank sum test;
***FDR: False discovery rate correction of the p values.
doi:10.1371/journal.pone.0007994.t001
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tyrosines on the cytoplasmic tail of EGFR were found to be
statistically different, exhibiting greater levels of phosphorylation
in cancer. The residues Y1172 and Y1197, are known to regulate
proliferative activity [20]. Interestingly, Y1172 is hyper-phosphor-
ylated (Tumor/Normal phosphorylation spectral count ratio .1)
only in adenocarcinoma (AD) samples. Y1197 is hyper-phosphor-
ylated in both AD and squamous cell carcinoma (SCC) subtypes,
but to a significantly higher degree in AD.
The site specific analysis revealed, somewhat surprisingly, that the
amino acid most consistently differentially phosphorylated in
normal and tumor tissue was Y34 of alcohol dehydrogenase 1B,
ADH1B ( less phosphorylated in tumors). This protein participates
in multiple related processes such as glycolysis, gluconeogenesis, and
fatty acid metabolism. Its expression is up-regulated in the late stage
of rat lung development, but down-regulated in human NSCLC
[21]. The specific role of Y34 is currently unknown, but the low
phosphorylation count may reflect either compromised enzyme
activity or the decreased protein abundance in tumors. With its role
in alcohol metabolism, this may be a consequence of the Warburg
effect whereby tumors employ aerobic glycolysis to meet their
metabolic needs [22]. ADH1B was recently identified as a risk
modifier for squamous aerodigestive cancers, with a postulated
mechanism of altered ethanol metabolism as being contributory
[23]. Another study noted decreased protein levels of ADH1B in
breast tumors [24], postulating the inability to oxidize the hydroxyl
group of retinol blocks the production of retinoic acid, a molecule
that helps maintain epithelial cells in their differentiated state.
There were many other differentially phosphorylated proteins.
Those hyperphosphorylated in tumors include multiple receptor
tyrosine kinases (listed in Table S2), and other signaling proteins,
such as p38 delta, protein kinase C delta, and members of the
PI3K signaling pathway, including p85 beta. Conversely, proteins
hypophosphorylated (Tumor/Normal phosphorylation spectral
count ratio .1) in tumors include the transcription factors
STAT1 and STAT5, the protein tyrosine phosphatase PTPN11,
the G-protein coupled receptor GPRC5A, and the kinases
MAPK1, MAPK3, and TNK2.
Highly Accurate Classification of Tumor Tissue via Cross
Validation
In order to assess the potential utility of monitoring protein
activity via tyrosine phosphorylation data, we developed classifiers
to predict the cancer/normal phenotypes of individual samples. In
particular, we examined our ability to distinguish normal tissue from
cancers based on small set of phosphotyrosines. Table 2 summarizes
the performances of five predictive models we examined. Two of the
models were based on statistically selected sites that yield maximum
discriminating power between cancer and normal tissue. Three
models were based on biologically driven selection of sites from key
pathways associated with lung cancer. A regularized regression
model (aiming to reduce the likelihood of overfitting the data) based
on all significantly differentially phosphorylated protein sites (FDR q
value ,0.05) successfully predicted the sample classes with an
average classification accuracy of 0.925 and an area-under-the-
curve, AUC at 0.974 in a rigorous bootstrapped cross validation
analysis that carefully separates training on random subsets of the
data and testing on the remaining subset. The selection of most
informative sites used to construct the model was also done on
training data. The average number of phosphotyrosine sites used
across all bootstrap trials was 88.
We also investigated whether biologically informed models
based on relevant gene modules can deliver an equal accuracy.
Specifically, regression models based on genes in the MSigDB
‘‘Proliferation’’ protein-set (commonly referred to as ‘‘gene sets’’ in
the microarray literature) [25], and two different protein-sets
representing the EGFR pathway, were also shown to discriminate
between normal and tumor samples with high accuracy. For the
EGFR pathway, we considered two representations: a ‘‘core’’
pathway with 11 proteins (Biocarta) and an ‘‘expanded’’ pathway
with 47 proteins (HPRD). The proteins are listed in Table S3. Our
results suggest that while the core EGFR proteins do provide a
reasonable accuracy in distinguishing cancer versus normal tissue
(0.83 AUC), the ‘‘expanded’’ EGFR pathway, with additional
proteins, performs significantly better (0.96 AUC). The most
informative proteins in the expanded pathway not included in the
core EGFR network are CAV1, GAB1, PXN, and PTPN11.
Lastly, a model based on the top 20 performing sites has an
average classification accuracy of 0.88 and AUC at 0.94. This
classifier supports the feasibility of building a relatively inexpensive
chip using very few sites as markers to enable detection of cancer
cells based on phosphorylation assays.
These results, taken together, indicate that the phosphorylation
status of proteins can be used to develop models that predict a
malignant phenotype of clinical samples with very high accuracy,
Table 2. The performances of the predictive models for normal/tumor classification.
Marker Sites Used in the Regression Models
Classification
Accuracy (95% C.I.) AUC (95% C.I.)
Average No. of Marker
Sites in the Model
Differentially phosphorylated sites 0.925 0.974 88
(0.833,0.986) (0.925,1.000)
Proliferation category 0.81 0.912 17
(0.712,0.859) (0.858,0.945)
EGFR pathway from BioCarta 0.764 0.826 12
(0.637,0.85) (0.718,0.894)
EGFR signaling network from HPRD 0.887 0.957 47
(0.791,0.961) (0.892,0.991)
Top 20 sites 0.883 0.944 20
(0.757,0.962) (0.820,0.995)
Shown in the table are the mean classification accuracy and AUC across the 100 bootstraps. The 95% bootstrap confidence intervals (C.I) of the accuracy and AUC are in
the parentheses.
doi:10.1371/journal.pone.0007994.t002
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similar to the performance reported from mRNA expression (see
Note S1) [26].
Highly Accurate Classification of Cancer Tissue via
Prediction on an Independent Validation Dataset with 16
NSCLC Samples
We applied two regression models trained from the 142 samples
to an independent dataset consisting of 16 NSCLC samples. The
coefficients used to integrate the phosphorylation level of proteins
in the two models are shown in supplementary Table S4 and S5.
At 90% sensitivity for cancer patients in the training data, the
statistical model using the 20 most informative phosphorylation
sites has 87.5% sensitivity on the validation samples. We repeated
the analysis using the ‘‘Proliferation Genes’’ category from the C2
database of MSigDB. The corresponding validation sensitivity is
93.8% which is slightly better than the sensitivity obtained by the
statistical model. The most informative sites used in the
proliferation module classifier are derived from EGFR and SYK
(Spleen Tyrosine Kinase).
Because we had no new independent normal samples to evaluate
the specificity of the classifiers, we adopted a variant of a resampling
approach to estimate the overall accuracy on the independent set
(described in the methods section). We report the average sensitivity,
specificity, accuracy, and AUC in Table S6. With seven samples left
out from training data, the new classifiers showed slightly reduced
sensitivity over the 16 validation cancer samples. The proliferation
module classifier showed better sensitivity but lower specificity than
the one based on statistically most informative markers. The
estimates of accuracy for these two classifiers ranged from 84 to
88%, and the estimated AUC is 92–93%.
Differential Phosphorylation of Cancer Associated
Pathways
To gain insight into biological processes whose activity may be
modulated in lung tumors, we tested 639 curated protein-sets
from the canonical pathway database of MSigDB to determine if
the overall phosphorylation levels of tyrosine sites in proteins
from each pathway are significantly different between normal
and tumor samples. We were not able to use traditional Gene Set
Enrichment Analysis [25] to detect these dysregulated pathways
due to the extreme sparsity of the data. Instead we associated a
metaprotein representation with each pathway and computed
whether the phosphorylation level of this metaprotein is
correlated to changes in phenotype. This technique is a new
variant of the metagene technique deployed for gene expression
analysis.
In total, 181 proteins observed in this dataset were a member
of at least one of the 639 protein-sets. Table 3 lists the top 15
protein-sets that display differential phosphorylation levels. The
protein-set that displays the greatest change in its overall
phosphorylation level when comparing normal and NSCLC
tissue is the KEGG pathway ‘‘HSA05211 RENAL CELL
CARCINOMA.’’ Of the 181 proteins considered here, 14 of
them belong to this protein-set, and 9 displayed high correlation
with the metaprotein phosphorylation levels. These 14 proteins
are shown in Supplementary Table S7, in which a positive
coefficient indicates higher phosphorylation in the tumor. Two
other pathways that are especially relevant for lung cancer that
have significantly different overall phosphorylation levels are
‘‘HSA05223 NON SMALL CELL LUNG CANCER’’ and
‘‘METPATHWAY BIOCARTA.’’ Five additional pathways are
explicitly related to cancer: ‘‘HSA05220 CHRONIC MYE-
LOID LEUKEMIA’’, ‘‘HSA05215 PROSTATE CANCER,’’
‘‘HSA05218 MELANOMA’’, ‘‘HSA05213 ENDOMETRIAL
CANCER’’ and ‘‘HSA05210 COLORECTAL CANCER.’’
Two pathways are generic for signaling pathways, ‘‘HSA04070
PHOSPHATIDYLINOSITOL SIGNALING’’ and ‘‘HSA04010
MAPK SIGNALING PATHWAY,’’ and the geneset with the
most members was the ‘‘INTEGRIN MEDIATED CELL
ADHESION GENMAPP,’’ with 32 observed and 28 correlated
proteins.
Table 3. The top 15 protein-sets from MSigDB C2 database for normal/tumor classification.
Pathway # Proteins # Corr Genes %Var FDR
HSA05211 RENAL CELL CARCINOMA 14 9 48 0.00041
HSA04540 GAP JUNCTION 10 6 44 0.0048
HSA04662 BCR SIG PATH 14 13 33 0.016
HSA04070 PHOSPHATIDYLINOSITOL SIGNALING 12 10 32 0.016
INTEGRIN MEDIATED CELL ADHESION GENMAPP 32 28 51 0.016
HSA05220 CHRONIC MYELOID LEUKEMIA 13 7 49 0.019
HSA05120 EPITHELIAL CELL SIGNALING HP INF 17 7 81 0.019
METPATHWAY BIOCARTA 24 20 55 0.019
HSA05223 NON SMALL CELL LUNG CANCER 12 6 52 0.019
ST DIFFERENTIATION PATHWAY IN PC12 CELLS 12 8 53 0.019
HSA05215 PROSTATE CANCER 13 6 52 0.019
HSA05218 MELANOMA 13 6 52 0.019
HSA05213 ENDOMETRIAL CANCER 13 6 52 0.019
HSA05210 COLORECTAL CANCER 14 8 50 0.019
HSA04010 MAPK SIGNALING PATHWAY 15 10 80 0.019
The protein-set name is listed in column 1. The number of proteins observed from that protein-set are reported in column 2. Column 3 reports the number of proteins
within the protein-set that are most responsible for the differential phosphorylation of the metaprotein. Column 4 reports the percentage of the metaprotein’s variation
that is differential in tumor and normal tissue. Column 5 reports the FDR q-value measuring the significance of the differential phosphorylation of the metaprotein
associated with the pathway in cancer.
doi:10.1371/journal.pone.0007994.t003
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Because of its pivotal role in lung cancer, we examined the
EGFR pathway in greater detail. In figure 1, we map all the
observed tyrosine phosphorylation events onto constituent pro-
teins, with a model constructed from the KEGG and HPRD/
NetPath databases. As expected, EGFR and many downstream
proteins in the pathway are differentially phosphorylated in
NSCLC samples. In total, 10 tyrosine sites are more phosphor-
ylated in tumors (pink), 7 more phosphorylated in normal tissue
(green) and 12 proteins were phosphorylated to a similar degree in
both sample types. Although no clear pattern is readily evident, it
is perhaps surprising to observe that the tyrosines Y186 and Y204
on ERK1 and ERK2 respectively are less phosphorylated in lung
tumors. It has been observed many times that excess phosphor-
ylation of ERK1/2 can result in cell cycle arrest, reviewed in [27],
and thus the lower levels observed in tumors could result in
increased cell-cycling, however, this requires additional study.
Phosphorylation Analysis of Different Tumor Subtypes
The histopathological distinction of AD and SCC can be
challenging [28], but with different treatment options available
[29], an important one. We analyzed phosphorylation level
differences between AD and SCC tissues at the levels of individual
sites, pathways and protein-sets.
To our surprise, there are no individual sites that are statistically
differentially phosphorylated in the two tumor subtypes in the
current dataset. Similarly, employing the metaprotein analysis
described above, we observe no significantly differentially
phosphorylated pathways or protein-sets (Supplementary Table
S8). The previously discussed gene models for tumor subtype
classification were evaluated, with results summarized in Supple-
mentary Table S9. The only classifier that performs reasonably
well, with AUC =0.78, is based on EGFR features selected
manually with emphasis on sites observed frequently (without
consideration of cancer subtype). Assuming that all samples were
diagnosed correctly, these results suggest that the differences of
phosphorylation measurements between AD and SCC are small
and hard to detect with pure statistical or machine learning
methods. We expect that a more quantitative analysis using
relative peak areas, as opposed to spectral counts, would likely
perform better for this task.
Figure 1. The EGFR signaling pathway. Pink indicates higher phosphorylation in tumor samples, while green indicates higher phosphorylation in
normal tissue samples. Yellow nodes were observed to be phosphorylated, however did not change significantly in the two types. Gray nodes were
not observed in the analysis. A red arrow (or edge) relates a kinase to its target, green edges indicate a phosphatase and its target. Blue edges
indicate activation, which may not be direct. Finally, a diamond shape on the end of an edge indicates phosphorylation, while a circle indicates an
inhibition of phosphorylation. Arrowheads indicate activation, which may be indirect.
doi:10.1371/journal.pone.0007994.g001
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Comparison of Classifiers Based on mRNA Expression
Data with Phosphotyrosine Data
For comparison, we include in the supplement a report on the
accuracies of classifiers based on mRNA expression. Based on
current data, it appears that phosphorylation status and mRNA
expression are roughly equally informative with respect to
classifying samples as tumors or normal. For distinguishing tumor
subtypes, phosphotyrosines work reasonably well (AUC ,0.78),
but classifiers built with mRNA transcript levels perform
significantly better (AUC ,0.98). Neither type of data is successful
at distinguishing early stage (stage I and II) from late stage tumors
(stage III and IV). However, this ‘‘failure’’ may reflect the similar
biology of the primary tumors in the two cases, which may not
change significantly as metastases colonize distant sites. Interest-
ingly, we do not observe a significant correlation between those
mRNA levels that are differentially expressed, and differential
tyrosine phosphorylation levels of the related protein product,
highlighting the complementary nature of the information
provided by activity-based measures.
Discussion
The results presented in this paper open the door to a number
of future directions in both basic and translational research.
Understanding the precise role of phosphorylation measurement
in regulation of signaling pathways in cancer remains an important
challenge, and we primarily focused on the role of EGFR and cell
proliferation pathways. We have identified a set of tyrosine
residues that are differentially phosphorylated in cancerous and
normal lung tissue. More than mRNA transcript or protein
expression levels, the phosphorylation status of select residues are
related to the functional activity of the associated gene products.
This is potentially particularly important in cancers as the
presence or absence of various receptor proteins may not reflect
the activity of downstream signaling intermediates. This scenario
could be important in at least two cases with respect to signaling
pathways, one in which a receptor is present, but there is no
activating ligand (or an abundance of a non-functioning ligand) to
initiate downstream signaling events, or if the receptor is present,
but mutated and inactive and therefore unable to transmit the
binding signal.
As in any systematic genome-scale survey, the observation of
unexpected results challenges the ability to derive explanatory
hypotheses. Such is the case with the observation that ADH1B is
the most differentially phosphorylated protein, with decreased
amounts observed in tumors. Implicated in squamous aerodiges-
tive tumors [23] where a prominent role in the metabolism of
ingested ethanol is compelling, it may be the case that in lung
tumors, tumor-associated hypoxia may be altering cellular
carbohydrate metabolism.
The central result of the analyses presented here is the
demonstration that signatures based on the differential phosphor-
ylation of tyrosine residues exhibit robust performance at
classifying cancer from normal tissue. This is true regardless if
the signature is based on a large number of protein sites, a smaller
number, or pathway-specific residues. This result was confirmed in
both rigorous cross validation study as well as on an independent
set. The classification accuracy of cancer vs. normal tissue is
essentially equivalent to the results obtained by microarray
experiments, even when performed on bulk-dissected tissues.
Tyrosine kinases that are hyperphosphorylated in lung tumors
are hypothesized to be inappropriately activated, and can
therefore be regarded as potential therapeutic targets for
inhibition. In this study, we observe up to 19 tyrosine kinases
that have statistically different phosphorylation levels between lung
cancer and normal tissue, and nearly all of those are hyperpho-
sphorylated in lung tumors (Supplementary Table S2).
The activation of multiple tyrosine kinases in a given cancer has
been previously observed in glioblastoma multiforme [30]. In that
case, combinations of tyrosine kinase inhibitors (TKIs) were
necessary to substantially reduce cell viability. Rather than
combinations of drugs, an alternative is to employ a multi-kinase
inhibitor, such as imatinib, sorafenib and sunitinib, which are each
individually capable of inhibiting multiple tyrosine kinases [31].
This led us to explore the possible existence of a multi-kinase
inhibitor that targeted a large fraction of those kinases that we
observed to be hyperphosphorylated in lung cancer. A compre-
hensive, publicly available dataset of TKI binding data [32]
assayed 38 TKIs against 317 kinases. We integrated TKI binding
data with our differential phosphorylation analysis (Supplementary
Table S2). Of the tyrosine kinsases for which binding data was
reported, and we find that, nearly all of them were bound by the
TKI dasatinib with high affinity (Kd’s ,2 nM). This would
suggest that dasatinib could potentially be a useful therapy for a
selection of patients with lung cancer. More generally, our study
illustrates the utility of integrating global tyrosine phosphorylation
assays [14] with drug binding data to quickly arrive at potential
therapeutic options, and the possibility of predicting a response to
particular kinase inhibitors.
Analysis of pathway-specific total-phosphorylation levels dem-
onstrates the specificity of the overall approach, as 7 of the top 15
protein-sets identified are explicitly defined as cancer protein-sets.
Signaling pathways accounted for 4 of the remaining top 15
protein-sets, including the important examples of phosphatidyli-
nositol and MAPK signaling pathways. Pathways downstream of
the EGFR and Met receptors, with prominent roles in lung cancer
biology, were similarly implicated.
While the performance of phosphotyrosine signatures was
modest for the discrimination of AD and SCC, with the top
performing classifier having an AUC of 0.78, mRNA transcript
levels classify these subtypes with higher accuracy, and neither
method distinguishes early from advanced stages of lung cancers.
The latter observation may reflect a limitation of the method, or it
may accurately reflect the biology of lung cancers, in that
fundamentally new processes are not needed for progression, only
that enough time has elapsed for the dysregulated genes and
pathways to erode further into surrounding tissue and that
metastases have occurred.
Future challenges for the characterization of tumors based upon
phosphorylation signatures include the relative sparseness of data
(especially among multiple samples), the convolution of protein
levels with phosphorylation levels, and the semi-quantitative
nature of spectral counting for measuring peptide abundance.
However, straightforward improvements exist to address each of
these limitations. It is likely that the most significant improvement
would result from the use of stable isotope labels. These would
allow direct comparisons among multiple samples, and increase
quantitative accuracy. The fact that such excellent performance
for classifying normal versus tumor tissue can already be achieved
makes further improvements highly desirable. Another promise is
the potential to develop signatures to guide treatments and predict
patient outcomes. Kinase inhibitors are an exciting new class of
treatments for cancer [33,34], however, recent studies have
emphasized that single targets of inhibition may not be sufficient
to achieve a therapeutic response [30]. Combinations of kinase
inhibitors, with each potentially binding to multiple targets, may
be necessary to inhibit undesirable growth and proliferation signals
active in neoplasms [35]. The phosphorylated proteins analyzed
Phospho-Signatures of Cancer
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here represent targets of kinases that should likely be inhibited to
achieve efficacy. Computational [36] or experimental [37]
methods for inferring the active kinases will potentially assist in
the identification of the relevant therapeutic targets in individual
cases.
Conclusions
Because the inappropriate activation of signaling pathways
represents fundamental biological processes in cancer, we
analyzed phosphorylation data from lung cancer and normal lung
tissue to identify differences. We identified several hundred
differentially phosphorylated sites in lung cancer, and developed
novel computational methodology to identify pathways whose
phosphorylation is dysregulated. Lastly, we demonstrated the
ability to classifying lung cancers with high accuracy based on
multi-variate phosphorylation signatures. The phosphorylation
sites identified provide an immediate set of novel drug targets, and
an analysis of the complement of sites provides a logic for the
selection among potential treatments using multi-targeted kinase
inhibitors or combinations of selective inhibitors.
Materials and Methods
Data Sources
The procedures of the experiments and the acquisition of the
tyrosine-phosphorylation data were described in the previous
publication [14]. The first dataset contains 151 NSCLC and 48
normal lung samples. Of the 151 tumor samples, 42 adenocar-
cinoma (AD) samples and 52 squamous cell carcinoma (SCC)
samples with available clinical information were used in the
classification analysis. Most of the 4551 observed phosphorylation
sites were identified in a relatively small number of samples. For
our analyses, we included those sites that were phosphorylated in
at least 10% of the samples under consideration. A second dataset
consisting of 16 NSCLC samples that were not originally included
in [14] (and are therefore previously unpublished) were used to
provide an independent validation of the predictive signature.
Statistical Analysis for Differential Phosphorylation of
Protein Sites between Sample Classes
For each site, phosphorylation levels were based on spectral
counts [38]. The statistical significance of the spectral count
difference between normal and tumor samples was evaluated by
the Kruskal-Wallis rank sum test. This non-parametric method-
ology was employed because the distribution of counts did not
observe a normal distribution. The p values were corrected for
multiple hypotheses using FDR q values [39]. Peptides with q
values ,0.05 were considered to display statistically significant
differential phosphorylation in tumor samples. We identify sites
that are both ‘‘hyper-phosphorylated’’ in tumor samples (Tumor/
Normal phosphorylation spectral count ratio .1) and ones that
are ‘‘hypo-phosphorylated’’ in tumor samples (Tumor/Normal
phosphorylation spectral count ratio ,1).
Logistic Regression Models to Predict the Sample
Phenotypes
For the classification of tumor samples and normal tissue we
applied a variant of a standard methodology. Five logistic
regression models with different gene sets were constructed for
sample phenotype classification. The first model uses all protein
sites that were significantly differentially phosphorylated between
two sample classes as the marker features (FDR q value,0.05 with
Kruskal-Wallis rank sum test). Then we trained a ridge logistic
regression model to fit the binary sample classes with the
phosphorylation profiles of the marker protein sites by the
procedures in an R package ‘‘penalized’’ [40]. This methodology
was chosen to reduce overfitting by penalizing ‘‘model complex-
ity’’ implemented in the ridge regression. An optimal penalty
parameter was chosen based on the cross-validation. Models 2–4
use sets of genes that are biologically known to be related to the
formation of lung cancer. Model 2 used the phosphorylated sites
from ‘‘Proliferation genes’’ from the MSigDB C2 database [25] as
the marker sites to train the logistic regression model. Models 3
and 4 used the protein sites in the EGFR pathway from two
sources: a smaller core pathway protein set from BioCarta (www.
biocarta.com) and a larger EGFR related protein interaction
network from HPRD/NetPath [41]. Finally, we compare the
performance of a minimal model, using only the top 20
performing phosphorylated tyrosines from our analysis above.
Estimation of Model Performance for Prediction of
Sample Phenotypes
To account for the potential bias due to the use of the same
dataset for both model construction and model evaluation, we
deployed a contextually novel strategy, based on the 0.632+
bootstrap approach [42,43], to support the statistical validity of the
relative accuracy of the classifiers reported in this paper. The
approach provides a bias-corrected estimate of the prediction error
by combining the bootstrap and the cross-validation, which has
shown to perform better compared to the standard cross-
validation approach [42,44].
In each bootstrap instance, we created a bootstrap sample by
selecting 142 observations with replacement from the original
data, which on average are composed of roughly 90 unique
patients. The bootstrap sample would be used as the training data
for constructing logistic regression models to be used for assigning
model scores. A cut-off value of the model scores which
corresponds to the minimal classification errors in the training
samples was taken as the classification threshold. Subsequently, we
use the validation data, consisting of all the observations not in the
training data, to evaluate the performance of the prediction.
In the validation data, we classify a sample with model score
larger than the threshold as tumor and those below the threshold
as normal tissue. We computed the overall classification accuracy
as the fraction of samples whose phenotype classes were correctly
predicted. We let the threshold value vary to plot a receiver
operating characteristic (ROC) curve for each model using the
standard methodology of increasing the threshold and document-
ing the corresponding error rates. The overall accuracy was
summarized based on the area under the ROC curve (AUC)
values. The bootstrap procedure was carried out 100 times.
Finally, bias-corrected estimates of the accuracy measures were
obtained based on the 0.632+ method [42]. To assess the sampling
variability of the estimated accuracy, we used the standard 95%
bootstrap confidence intervals, defined by the ranges between the
2.5th and the 97.5th percentiles. The expected AUC for a random
non-informative model is 0.5. A classification model was
considered significantly predictive of the phenotypes only if the
lower bound of the 95% confidence intervals of the AUCs is larger
than the null AUC value.
Significant Correlation of the Overall Phosphorylation of
Pre-Defined Protein-Sets to Phenotypes
Due to the fact that, in general, mass spectrometric measure-
ment of low abundance proteins is extremely sparse, we developed
a metaprotein analytic approach for the analysis of pathway
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specific phosphorylation changes, based on pathways from
MSigDB. A metaprotein is defined as a specific linear combination
of selected phosphorylation sites from proteins within a curated
protein-set. In the first step, for each protein-set P, we utilized
principal component analysis on the phosphorylation profiles of
the protein sites belonging to P in all 142 samples to define
eigenvectors that reflect the variation in observed phosphorylation
patterns [45]. Principal components were only considered if they
explained a significant amount of the variation in metaprotein
phosphorylation (.30%) and had 10 or more phosphotyrosine
sites observed in the data. The metaprotein phosphorylation is
defined as the sum of the phosphorylation counts of individual
protein sites weighted by the coefficients in the eigenvectors
corresponding to the principal components. Metaproteins with
differential phosphorylation in normal tissues and tumors were
identified using the Kruskal-Wallis rank sum test. Pathways with
FDR q values less than 0.02 were considered significant. Lastly, the
Pearson correlation coefficient between each phosphorylated
residue and the metaprotein was computed in order to identify
those proteins within the pathway that are most responsible for the
observed global variation. This approach appears to be an
effective methodology for identifying differentially phosphorylated
pathways using proteomic data and should be broadly applicable
to other types of extremely sparse data. Traditional Gene Set
Enrichment Analysis [25] was not readily applicable to this type of
data due to the fact that relatively few measurements per pathway
were available. Combining principal component analysis, PCA, on
each pathway with correlation of the derived metaproteins to
phenotype produced results that are both consistent with literature
as well as new findings.
Validation on a New 16-Sample NSCLC Dataset
We compiled a set of 164 protein sites which are present both in
the 142-sample and the new datasets. The most informative 20
sites on the training set were used as markers. We applied a ridge
logistic regression model as described in previous sections.
Multiple cutoff values of the regression scores were chosen
corresponding to different sensitivity levels on the training dataset.
We repeated the model construction and validation using 12
protein sites from the ‘‘Proliferation Genes’’ set in the C2 category
of MSigDB database.
Estimation of Specificity, Accuracy, and AUC of the
Models
We randomly chose and excluded seven normal samples from
the old larger dataset, and combined these normal subjects with
the 16 new cancer samples to form a validation dataset. Each time
we retrain a new regression model on the remainder of the
training dataset with the top 20 differential sites or proliferation
category proteins respectively. The feature selection was carefully
performed only on training data. We repeated the resampling 100
times. The cutoff was also determined at each run, and was based
on the threshold at 90% sensitivity on training samples only.
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